Navigation Links
Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
Date:3/26/2009

es to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "plan," "should," "target," "will," "would," and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our critical accounting estimates and risks relating to our ability to realize anticipated synergies and cost savings from our October 2008 merger; our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR tablets; the possibility that the Food and Drug Adminis
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
(Date:8/21/2014)... PA & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of ... to Japanese red cedar pollen. Phase IC studies began ... a real solution to hay fever. , The Japanese ... over 35 million people in Japan. Mountain Cedar pollen ...
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... June 3, 2010 Ben-Gurion University of the Negev students ... people maneuver around obstacles. The radar system incorporates a ... warn the blind of obstacles with audible alerts. The ... the depth of its surroundings, taken from two different angles ...
... HAYWARD, Calif. , June 3 Anthera Pharmaceuticals, Inc. ... diseases associated with inflammation and autoimmune disorders, today announced Colin Hislop ... of Anthera. Dr. Hislop replaces James E. Pennington , M.D., who ... , , ...
... June 3 Kendle (Nasdaq: KNDL ), ... it is ranked a top CRO to work with in ... only CRO to be ranked consistently among the top three ... annual U.S. and European site surveys conducted by CenterWatch, a ...
Cached Biology Technology:Ben-Gurion University students develop device to help blind manuever 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 4Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3
(Date:8/21/2014)... skin fungus linked to dandruff, eczema and other itchy, ... even further global reachesincluding Hawaiian coral reefs and the ... , A review in the scientific journal PLOS ... the fungi of the genus Malassezia in ... datasets from around the world. , University of Hawai,i ...
(Date:8/21/2014)... AWI geologist Juliane Mller the Fram Strait is a key ... of this passage between Greenland and Svalbard warm Atlantic water ... the west side cold Arctic water masses and sea ice ... Atlantic. A considerable portion of the Atlantic water cools here ... layers. The circulation of the water caused in this manner ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Prepared in distilled water....
in vitro Translation, Accessory Products...
Biology Products: